Skip to content

Seasonal flu & COVID19 vaccine

Posted on
Sometimes people are advised by their doctor not to have a vaccination within 12 months of having had GBS, as a precaution, so if your diagnosis was only a few months ago, your doctor might advise you to give it a miss this year, unless you are in a group considered to be at high risk from flu. Otherwise, the advice for people who have had GBS is basically the same as for anyone else regarding vaccinations. GBS is a single event acute condition that is very unlikely to recur; it doesn’t ‘relapse’ and someone who has had GBS is unlikely to get it again (recurrence rate is believed to be around 2-5%). The only caveat to this would be if you developed GBS within a few weeks following a vaccination, in which case it would be wise to avoid that particular vaccine in the future (the seasonal flu vaccine changes each year, depending on which strains are predicted by the WHO to be most prevalent:…/vaccines/virus/recommendations/en/).
An additional consideration is for anyone having recently received immunoglobulins. These might interfere with how the immune system responds following a vaccination, and can make vaccines less effective, so it may be advisable to avoid vaccinations for at least 6 weeks after receiving immunoglobulin treatment.
With regards to the seasonal flu jab in particular, the risk of this triggering GBS is far lower than the risk from flu itself. Under normal circumstances, most people don’t need a flu jab, because for them, flu is inconvenient but not life-threatening. However, if you are in an at-risk group, or you live or work closely with people for whom flu can cause severe and even life-threatening complications, then the advice is to be vaccinated, as this is the most effective way to protect yourself against getting flu, and passing it on to others. This year, things are a bit different, because in the absence of a COVID-19 vaccine, anyone getting flu and COVID-19 concurrently is potentially at a heightened risk. The flu vaccination programme for 2020/21 is being extended beyond those traditionally considered to be at risk, to minimise the spread and to protect as many people as possible from the associated danger.
According to the Medicines & Healthcare products Regulatory Agency (MHRA);
‘The balance of epidemiological evidence is not sufficient to confirm that currently used influenza vaccines are causally associated with the development of GBS. As GBS also occurs naturally in the vaccinated population, and particularly because flu-like illness is a known risk factor for GBS, a number of cases are reported each year in temporal association with vaccination. This does not mean the vaccine was the cause.
Recent data supports the findings made in previous studies that an influenza vaccination may trigger GBS in fewer than 1 in 1,000,000 people vaccinated. There were approximately 13,000,000 people vaccinated in the UK during 2017/18 and there were 10 reports submitted through the yellow card scheme for the same period. It should be understood that these may be true side-effects, or they may be due to concurrent diagnosed or undiagnosed illness, other medicines or they may be purely co-incidental events that would have occurred anyway in the absence of therapy. Based on current evidence, the MHRA findings are that these reports do not indicate a causal relationship between influenza vaccine and GBS.’
GAIN would also add that this is supported by independent research showing colds and flu-like illnesses to be known triggers for GBS. Because vaccines stimulate the immune system, theoretically this might exacerbate or lead to the appearance of an autoimmune disease, but it is not possible to identify those for whom a vaccine might act as a trigger, or why. The seasonal flu vaccination is considered to be a very low risk trigger, with approximately 1 case of GBS triggered per 1,000,000 vaccinations as opposed to 1 case of GBS per 60,000 cases of flu.
It is difficult to comment on the many COVID-19 vaccines that are currently under development, as they are still in the early stages of being tried and tested, but it would seem feasible that similar advice would follow. In this case, however, we know that unlike flu, only around 20% of people who test positive for COVID-19 actually show symptoms, and that as well as amongst high risk groups, COVID-19 can be fatal in younger people and people without co-morbidities who would not normally be considered at risk. The advice, once a proven vaccine is available, will probably be for everyone to have it, to limit the spread amongst the population as a whole, so protecting the most vulnerable.
On vaccinations in general, our Medical Advisory Board would offer the following advice:
· DON’T have a vaccine that was temporally associated with onset of GBS – that is probably within 6 weeks but 12 weeks if very conservative (this is related to an individual – not general and thus applies to very few people)
· DON’T have unnecessary vaccines for travel but DO have all other necessary travel vaccines
· DO have all vaccines that are ‘necessary’. This includes the flu vaccine and will include COVID vaccine, MMR, DTP, pneumovax, HIF etc. There is no population link to causation in any of these – there are monitoring programmes going on so a link would be picked up if it occurred; no links have been detected since the 1970s
As with many things in life, there is no simple ‘yes or no’ answer, and each person must weigh up the risks associated with not having a vaccination, against the very small risk that might be associated with having it. I hope the above helps you reach an informed decision.
< Back to news